Prof. Sandosh Padmanabhan is the Pontecorvo Chair of Pharmacogenomics at the University of Glasgow and an Honorary Consultant Physician at Queen Elizabeth University Hospital. A physician–scientist in pharmacogenomics, hypertension, and cardiovascular genomics, he leads translational programmes that combine real-world data, population genomics, and clinical trials.

Ruby is a pharmacist and PhD student from the School of Pharmacy at the University of Sydney. Her research focuses on the implementation of pharmacogenomics into routine clinical care to optimise medication therapy, improve patient safety, and enhance treatment outcomes.

Eman Wehbe is a PhD student at the University of Sydney School of Pharmacy, with a focus on clinical pharmacology and pharmacogenomics. Her research focuses on implementing pharmacogenomic testing in the Australian aged care setting to support more personalised and safer medication use for older adults.

Dr. Pajaree Chariyavilaskul earned her Medical Doctor degree with honors from the Faculty of Medicine at Chulalongkorn University, Bangkok, Thailand, in 2001. She then pursued post-graduate training, obtaining an M.Sc. in Clinical Pharmacology with Distinction from the University of Glasgow, UK, in 2004, followed by a Ph.D. in Medical Science from the University of Edinburgh, UK, in 2010. She is currently an Associate Professor of Pharmacology and Assistant Dean of Research Affairs at the Faculty of Medicine, Chulalongkorn University. Dr. Chariyavilaskul holds several key leadership positions, including Director of the Center of Excellence in Clinical Pharmacokinetics and Pharmacogenomics, Head of Pharmacogenetics Laboratory Services at the Center for Medical Diagnostic Laboratories, executive member of the Steering Committee for the Maha Chakri Sirindhorn Clinical Research Centre under the Royal Patronage, and executive member of the Scientific Committee for Phase I Clinical Trials under the Central Research Ethics Committee (CREC), Thailand. In her academic role, Dr. Chariyavilaskul teaches pharmacology across undergraduate and postgraduate programs. Her research focuses on clinical pharmacokinetics, pharmacodynamics, and pharmacogenomics, with a strong emphasis on precision medicine and translational applications in Thai populations.

Ying Ke is a Scientific Leader at GSK R&D. His work supports drug development across all phases — from preclinical through regulatory approval — with expertise in assessing across population differences in drug target, ADME, PK-PD, and disease clinical/pathophysiology. Ying’s work at GSK supports strategy for global simultaneous development to deliver better outcomes for diverse patient populations.

Dr Shubham Atal is an Additional Professor of Pharmacology at the All India Institute of Medical Sciences (AIIMS), Bhopal, India. He is a clinician-scientist with academic and research interests in clinical pharmacology, precision medicine in psychiatry and oncology, rational use of medicines, drug interactions and management of NCD’s. Having completed his MBBS, MD (Pharmacology) from India and MSc (Clinical Research) from Ireland, he is currently pursuing his PhD focusing on pharmacogenetics of antidepressant treatment response. He has completed brief stints as visiting faculty at the Harvard Medical School, Boston and a fellowship in personalised healthcare from Erasmus Medical Center, Rotterdam. Dr Atal has authored multiple peer-reviewed publications and is actively involved in undergraduate and postgraduate medical education, clinical research methodology, and institutional drug policy initiatives. His ongoing work aims to translate pharmacogenetic insights into personalized and evidence-based care.